Tocagen shoots for $86 million IPO, spotlighting a high-risk shot at a quick OK for brain cancer therapy
A couple of weeks after Tocagen nabbed the FDA’s breakthrough therapy designation for a new treatment for recurring brain cancer, the San Diego-based biotech is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.